Related Experiment Video
Updated: Dec 28, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer
Huiping Qiang1, Qing Chang1, Jianlin Xu1
1Department of Respiratory Medicine, Shanghai Chest Hospital, Jiaotong University, Huaihai West Road No. 241, Shanghai, 200030, People's Republic of China.
Purpose:
Tumor growth relies on the sufficient blood supply and continuously requires new blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med 285:1182-1186, 1971). Antiangiogenic therapy has emerged with the goal of normalizing vasculature and tumor microenvironment (TME). Some antiangiogenic therapies combined with chemotherapy, targeted therapy or immunotherapy have been approved for clinical application. In this review, we summarize the recent advances of antiangiogenic combination therapeutic strategies in advanced NSCLC.
Methods:
References of this review are searched through PubMed and EMBASE and the abstracts of cancer conferences. The ClinicalTrials.gov database was used for relative trials.
Results:
Based on different mechanisms, antiangiogenic agents can be divided into monoclonal antibodies (mAbs), which mainly include bevacizumab and ramucirumab, and multi-target antiangiogenic tyrosine kinase inhibitors (TKIs) which include sunitinib, sorafenib, nintedanib, apatinib, anlotinib, fruquintinib, etc. In recent years, a number of large clinical studies have shown that antiangiogenic agents have conferred a significant overall survival (OS) benefit to patients with advanced non-small cell lung cancer (NSCLC). More and more evidences confirm that the combination of antiangiogenic agents with chemotherapy, targeted therapy and immunotherapy can improve the effect and prolong the survival of NSCLC patients. However, many problems about the application of antiangiogenic agents on advanced NSCLC patients still need to be explored. For example, the combination therapy of multi-target antiangiogenic agents is just beginning, and the biomarkers are not clear.
Conclusions:
Antiangiogenic agents can achieve therapeutic benefit in advanced NSCLC patients and the combination of chemotherapy, targeted therapy or immunotherapy can lead to synergistic effect. However, exploring the best combination therapy and efficacy-related biomarkers needs further study.
Insights
Antiangiogenic therapies show significant survival benefits for advanced non-small cell lung cancer (NSCLC). Combining these agents with chemotherapy, targeted therapy, or immunotherapy enhances treatment effectiveness and patient outcomes in NSCLC.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Tumor growth necessitates a robust blood supply, often leading to abnormal vasculature.
- Antiangiogenic therapy aims to normalize tumor vasculature and the tumor microenvironment (TME).
- Combination strategies involving antiangiogenic agents are increasingly approved for clinical use.
Purpose of the Study:
- To review recent advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer (NSCLC).
Main Methods:
- Literature search of PubMed, EMBASE, and cancer conference abstracts.
- Inclusion of relevant clinical trials from ClinicalTrials.gov.
Main Results:
- Antiangiogenic agents include monoclonal antibodies (e.g., bevacizumab) and multi-target tyrosine kinase inhibitors (TKIs) (e.g., nintedanib, anlotinib).
- Clinical studies demonstrate significant overall survival (OS) benefits for advanced NSCLC patients treated with antiangiogenic agents.
- Combinations with chemotherapy, targeted therapy, and immunotherapy improve efficacy and prolong survival in NSCLC patients, though challenges remain.
Conclusions:
- Antiangiogenic agents offer therapeutic benefits in advanced NSCLC.
- Combination therapies (chemotherapy, targeted therapy, immunotherapy) exhibit synergistic effects.
- Further research is needed to optimize combination strategies and identify efficacy-related biomarkers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy